DOJ Sends Subpoena to Seek Exparel Marketing Documents From Pacira

Pacira Pharmaceuticals Inc. April 16 said it has received a subpoena from the Department of Justice asking for documents related to the marketing of its drug Exparel (bupivacaine liposome injectable suspension).

In a press release, the company said it received a subpoena from the U.S. Attorney’s Office for the District of New Jersey asking Pacira to produce “a broad range of documents pertaining to marketing and promotional practices related to the product Exparel.”

Pacira said it intends to cooperate with the government’s investigation.

Exparel is a non-opioid local analgesic indicated for administration to a surgical site to relieve pain there ...